To Evaluate Ezetimibe/Simvastatin and Niacin (Extended Release Tablet) in Patients With Type IIa or Type IIb Hyperlipidemia (0653A-091)(COMPLETED)

Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin and Niacin (Extended Release Tablet) Co-Administered in Patients With Type IIa or Type IIb Hyperlipidemia

To evaluate the efficacy and safety of ezetimibe/simvastatin and niacin in patients with high cholesterol.

Inclusion Criteria:

• Patient with LDL-C of 130 through 190 mg/dL and Triglycerides less than or equal to 500 mg/dL
• Patient willing to be on a low-cholesterol diet

Exclusion Criteria:

• Pregnant or lactating women or intending to become pregnant
• Patient with sensitivity or intolerance to ezetimibe, simvastatin, or ezetimibe/simvastatin combination tablet
• Patient with sensitivity or intolerance ro niacin, any component or niacin extended release or aspirin
• Patient for whom discontinuation of existing lipid-lowering therapy treatment poses an unacceptable risk